(19)
(11) EP 1 350 262 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
13.08.2008 Bulletin 2008/33

(45) Mention of the grant of the patent:
11.06.2008 Bulletin 2008/24

(21) Application number: 01273824.1

(22) Date of filing: 10.12.2001
(51) International Patent Classification (IPC): 
C12N 15/11(2006.01)
 A61K 31/70(2006.01)
(86) International application number:
PCT/IB2001/002888
(87) International publication number:
WO 2002/069369 (06.09.2002 Gazette 2002/36)

(54)

CPG-LIKE NUCLEIC ACIDS AND METHODS OF USE THEREOF

CPG-ARTIGE NUKLEINSÄUREN UND VERFAHREN ZU IHRER VERWENDUNG

ACIDES NUCLEIQUES DU TYPE CPG ET PROCEDES D'UTILISATION CORRESPONDANTS

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

(30) Priority: 08.12.2000 US 254341 P

(43) Date of publication of application:
08.10.2003 Bulletin 2003/41

(60) Divisional application:
08157972.4

(73) Proprietor: Coley Pharmaceutical GmbH
40225 Düsseldorf (DE)

(72) Inventors:
  • SCHETTER, Christian
    40723 Hilden (DE)
  • VOLLMER, Jörg
    40591 Düsseldorf (DE)

(74) Representative: Jump, Timothy John Simon et al
Venner Shipley LLP 20 Little Britain
London EC1A 7DH
London EC1A 7DH (GB)


(56) References cited: : 
WO-A-01/93903
   
  • GOECKERITZ B.E. ET AL.: "Multivalent cross-linking of membrane Ig sensitizes murine B cells to a broader spectrum of CpG-containing oligodeoxynucleotide motifs, including their methylated counterparts, for stimulation of proliferation and Ig secretion" INTERNATIONAL IMMUNOLOGY, vol. 11, no. 10, 1999, pages 1693-1700, XP000938323
  • BOGGS R.T. ET AL.: "Characterization and modulation of immune stimulation by modified oligonucleotides" ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, vol. 7, 1 October 1997 (1997-10-01), pages 461-471, XP002053418 ISSN: 1087-2906
  • YAMAMOTO T. ET AL.: "Lipofection of synthetic oligodeoxyribonucleotide having a palindromic sequence of AAGCTT to murine splenocytes enhances Interferon production and natural killer activity" MICROBIOLOGY AND IMMUNOLOGY, vol. 38, no. 10, 1994, pages 831-836, XP008012406
  • HENRY S. ET AL.: "Chemically modified olioligonucleotides exhibit decreased immune stimulation in mice" THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 292, no. 2, February 2000 (2000-02), pages 468-479, XP002310045
  • ZHAO Q. ET AL.: "Immunostimulatory activity of CpG containing phosphorothioate oligodeoxynucleotide is modulated by modification of a single deoxynucleoside" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 10, no. 10, May 2000 (2000-05), pages 1051-1054, XP004204603 ISSN: 0960-894X
  • KRIEG A.M.: "Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides" BIOCHIMICA ET BIOPHYSICA ACTA . GENE STRUCTURE AND EXPRESSION, ELSEVIER, AMSTERDAM, NL, vol. 1489, no. 1, 10 December 1999 (1999-12-10), pages 107-116, XP004275526 ISSN: 0167-4781
  • BAILLY C. ET AL.: "Recognition elements that determine affinity and sequence-specific binding to DNA of 2QN, a biosynthetic bis-quinoline analogue of echinomycin" ANTI-CANCER DRUG DESIGN, vol. 14, 1999, pages 291-303, XP008040033
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).